Shelly T Lee1, Ron A Adelman. 1. Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, Connecticut 06510, USA.
Abstract
PURPOSE: To study the effect of intravitreal bevacizumab injection in recurrent central serous chorioretinopathy (CSC). METHODS: Retrospective case series. Patients followed at the Yale Eye Center with a diagnosis of recurrent CSC who were treated with intravitreal bevacizumab from January 2007 to January 2009 were studied. Intravitreal injections of bevacizumab were given once every 4 weeks until sub-retinal fluid resolved. We collected preinjection visual acuity, optical coherence tomography (OCT), fluorescein angiography imaging, number of injections administered, OCT data after each injection, and visual acuity after each injection. Each patient was followed for a minimum of 6 months. RESULTS: Three patients met the inclusion criteria. All patients were men and aged from 39 to 46 years. All patients had recurrent disease. None had received prior treatment. Mean preinjection visual acuity was logMar 0.30, with a median of 0.30. Mean postbevacizumab visual acuity was 0.03, 0.07, and 0.03 at 1, 3, and 6 months, respectively. Median postbevacizumab acuity was 0, 0.10, and 0 at 1, 3, and 6 months, respectively. Baseline preinjection central macular thickness (CMT) by OCT imaging ranged from 320 to 500 μm, with a mean of 388 μm and a median of 344 μm. Mean CMT at month 1 was 248 μm, with a median of 190 μm. Mean CMT at month 3 was 252 μm, with a median of 281 μm. Mean CMT at month 6 was 273 μm, with a median of 187 μm. CONCLUSIONS: Bevacizumab may be an effective treatment option for patients with recurrent CSC. Although long-term efficacy is unknown, it is a relatively low-risk treatment option that may improve visual acuity and CMT.
PURPOSE: To study the effect of intravitreal bevacizumab injection in recurrent central serous chorioretinopathy (CSC). METHODS: Retrospective case series. Patients followed at the Yale Eye Center with a diagnosis of recurrent CSC who were treated with intravitreal bevacizumab from January 2007 to January 2009 were studied. Intravitreal injections of bevacizumab were given once every 4 weeks until sub-retinal fluid resolved. We collected preinjection visual acuity, optical coherence tomography (OCT), fluorescein angiography imaging, number of injections administered, OCT data after each injection, and visual acuity after each injection. Each patient was followed for a minimum of 6 months. RESULTS: Three patients met the inclusion criteria. All patients were men and aged from 39 to 46 years. All patients had recurrent disease. None had received prior treatment. Mean preinjection visual acuity was logMar 0.30, with a median of 0.30. Mean postbevacizumab visual acuity was 0.03, 0.07, and 0.03 at 1, 3, and 6 months, respectively. Median postbevacizumab acuity was 0, 0.10, and 0 at 1, 3, and 6 months, respectively. Baseline preinjection central macular thickness (CMT) by OCT imaging ranged from 320 to 500 μm, with a mean of 388 μm and a median of 344 μm. Mean CMT at month 1 was 248 μm, with a median of 190 μm. Mean CMT at month 3 was 252 μm, with a median of 281 μm. Mean CMT at month 6 was 273 μm, with a median of 187 μm. CONCLUSIONS:Bevacizumab may be an effective treatment option for patients with recurrent CSC. Although long-term efficacy is unknown, it is a relatively low-risk treatment option that may improve visual acuity and CMT.
Authors: George Joseph Manayath; Ratnesh Ranjan; Smita S Karandikar; Vanee Sheth Shah; Veerappan R Saravanan; Venkatapathy Narendran Journal: Oman J Ophthalmol Date: 2018 Sep-Dec